Cardio Diagnostics Holdings, Inc. (CDIO) is a Chicago-based, AI-driven precision cardiovascular diagnostics company that develops epigenetic and genetic blood tests, including Epi+Gen CHD and PrecisionCHD. As a micro-cap with a market capitalization of only about $5.6 million and negligible revenue, the company has essentially no current, credible analyst price-target coverage. Available third-party data is sparse and largely stale: some trackers reference a single dated target around $60 from early 2025, and others show an outdated low-to-high range near $4 to $8, but these figures predate the company's subsequent decline and heavy share dilution and do not form a usable consensus. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Because no reliable analyst average exists, the $2.50 figure is a fallback objective grounded in identifiable technical and psychological milestones rather than a sell-side forecast. It sits meaningfully above the current price, above the 200-day moving average near $2.06, and well below the 52-week high near $7.91. It should be read as a discussion-level reference point, not a published analyst consensus.
The stock last traded near $1.89, with a 52-week range of roughly $0.97 to $7.91. Reaching $2.50 implies an upside of about 32%, a substantial move given the company's scale and liquidity. The path would most plausibly involve a sustained recovery above the 200-day moving average (around $2.06) and the psychologically important $2.00 level, followed by momentum toward $2.50 as the next round-number resistance zone.
Fundamentally, the business remains at a very early commercialization stage. Trailing twelve-month revenue is only about $15,000, while the company reported a third-quarter net loss of roughly $1.73 million, or $0.59 per share. Any meaningful share-price advance would likely depend on evidence of accelerating test volumes and reimbursement rather than on current earnings, which are negative. From what I see, this remains the core dynamic to watch.
The 50-day moving average sits near $1.84 and the 200-day moving average near $2.06, meaning the stock is trading between these two trend benchmarks. The $2.00 area is a key psychological level, and $2.50 represents the next notable round-number resistance zone. Above that, the prior 52-week high near $7.91 shows how quickly this low-float name has repriced in the past, while the 52-week low near $0.97 highlights the downside risk. I also checked this using Tickeron’s AI Trend Prediction Engine to gauge momentum.
Analyst price targets, when available, typically reflect a roughly 12-month research horizon, but no current, dated institutional targets apply here, so no specific horizon should be assumed for the $2.50 objective. Investors should monitor upcoming earnings reports and revenue progression, reimbursement and coverage announcements, laboratory utilization data, any financing or dilution events, and the stock's ability to hold above its moving averages. Changes in the broader biotechnology and small-cap funding environment also matter.
In my own research process, Tickeron’s AI Daily Buy/Sell Signals have become a useful complement for volatile names like this one. The tool applies artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a thinly covered micro-cap like CDIO, it helps surface opportunities and track trend shifts more efficiently than manual methods alone. I find it particularly helpful for maintaining perspective amid the swings typical in this sector.
Whether CDIO can reach $2.50 depends less on valuation and more on execution. The roughly 32% move required is substantial for a company generating almost no revenue, yet it is well within the range this stock has traveled over the past year. Supporting factors, including the new in-house laboratory and early payer coverage, provide a plausible catalyst narrative, while persistent losses, dilution, and minimal liquidity represent the principal obstacles. With no reliable current analyst consensus, the $2.50 level is best viewed as a technical reference point to monitor, not a forecast or guarantee of future performance.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
The 10-day moving average for CDIO crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CDIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
CDIO broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CDIO's RSI Indicator exited the oversold zone, 40 of 50 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on CDIO as a result. In 41 of 64 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.
The Moving Average Convergence Divergence (MACD) for CDIO just turned positive on November 06, 2026. Looking at past instances where CDIO's MACD turned positive, the stock continued to rise in 21 of 38 cases over the following month. The odds of a continued upward trend are 55%.
CDIO moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +6.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where CDIO advanced for three days, in 113 of 154 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
The Aroon Indicator entered an Uptrend today. In 53 of 136 cases where CDIO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 39%.
The Tickeron PE Growth Rating for this company is 46 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. CDIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.654) is normal, around the industry mean (3.498). P/E Ratio (-0.566) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (322.581) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CDIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology